Pharmaceuticals, Biotechnology and Life Sciences
Barry Greene, a world-class leader with global experience and a significant track record of success in R&D and commercialization, joins as part of plan to accelerate the Sage mission to deliver truly transformational medicines for people with brain health disorders
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Sage Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, and is the first and only treatment specifically approved for postpartum depression (PPD), one of the most common medical complications during and after pregnancy.
ZULRESSO is the first and only treatment specifically indicated for postpartum depression SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced…
Sage Therapeutics got clearance from the FDA has approved Zulresso (brexanolone) injection for the treatment of postpartum depression (PPD), and is the first and only medicine specifically approved to treat PPD, the most common medical complication of childbirth.